Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prevail Therapeutics Inc. (NasdaqGS: PRVL) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Prevail will receive only $22.50 in cash plus one non-tradable contingent value right worth up to $4.00 per share in cash (subject to certain terms and conditions) for each share of Prevail that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (email@example.com) toll free at any time at 855-768-1857, or fill out the form on this page.
Please note that the merger is structured as a tender offer, such that time may be of the essence.